Drug Recall: Coated Back Relief Tablet CGMP Deviations
ULTRAtab Laboratories, Inc. voluntarily recalls approximately 25.8 million tablets of Coated Back Relief Tablet due to current good manufacturing practice (CGMP) deviations detected during production.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The source text identifies this as an FDA Class II recall for CGMP deviations. The source does not report any illnesses, injuries, or product defect outcomes; the hazard is procedural and precautionary in nature, warranting a Moderate severity score.
Plain-English summary
ULTRAtab Laboratories, Inc., located in Highland, New York, is voluntarily recalling approximately 25,769,495 tablets of Coated Back Relief Tablet (Acetaminophen 250 mg, Magnesium Salicylate 290 mg, Caffeine 50 mg) in bulk container form (NDC 62959-800-00). The recall was initiated on January 26, 2022, and classified by the FDA as Class II on February 9, 2022.
The recall is due to current good manufacturing practice (CGMP) deviations identified in the manufacturing process. The bulk product was distributed to three distributors, who may have distributed finished product to downstream customers.
Consumers or healthcare providers who have this product in stock should discontinue use and contact ULTRAtab Laboratories, Inc. for instructions on return or disposal. The recall was terminated on January 7, 2025.
The recalled product
- Product
- Coated Back Relief Tablet (Acetaminophen 250 mg, Magnesium Salicylate 290 mg, Caffeine 50 mg) Bulk Container, ULTRAtab Laboratories, Inc., Highland, NY NDC 62959-800-00
- Manufacturer
- ULTRAtab Laboratories, Inc.
- Hazard
- cgmp-deviation
- manufacturing-control
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- Product Codes: M800L Bulk Lots: 18K005
- 18K075
- 18K098
- 18M064
- 19C021
- 19C050
- 19G081
- 19G082
- 19H012
- 19H013
- 19J036
- 19J037
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27